IC
AVDL

Ikarian Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Ikarian Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-750,000
Closed -$5.96M – 177
2020
Q1 		$5.96M Buy
+750,000
New +$5.76M 0.45% 55

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Ikarian Capital's AVDL Position: Q1 2021 in Review

Ikarian Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2021, closing a stake of 54,694 shares — an estimated $366K sold.

Ikarian Capital first reported a position in AVDL in Q1 2020 and held it in 4 quarters. The position peaked at $3.94M in Q2 2020. 76 funds tracked by Wall St. Rank hold AVDL as of Q1 2021.

  • Ikarian Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Ikarian Capital sold 54,694 Avadel Pharmaceuticals shares in Q1 2021, an estimated $366K.
  • Ikarian Capital first reported a position in Avadel Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Ikarian Capital's Avadel Pharmaceuticals position peaked at $3.94M in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2021.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.